CARB-X Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CARB-X's estimated annual revenue is currently $5.4M per year.(i)
  • CARB-X's estimated revenue per employee is $155,000

Employee Data

  • CARB-X has 35 Employees.(i)
  • CARB-X grew their employee count by -5% last year.

CARB-X's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is CARB-X?

CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is led by Boston University and its funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services; the Wellcome Trust, a global charity based in the UK; Germany's Federal Ministry of Education and Research (BMBF); the UK Department of Health and Social Care's Global Antimicrobial Resistance Innovation Fund (UK GAMRIF); the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) within the HHS. CARB-X is investing more than $500 million from 2016-2021 to support innovative antibiotics and other therapeutics, vaccines and rapid diagnostics. CARB-X supports the world's largest and most innovative pipeline of preclinical products against drug-resistant infections. CARB-X focuses exclusively on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is headquartered at Boston University School of Law.

keywords:N/A

N/A

Total Funding

35

Number of Employees

$5.4M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CARB-X News

2022-04-17 - SNIPR BIOME Initiates First-in-Human Clinical Trial with ...

SNIPR001 has been granted Fast-Track designation by the FDA and is being developed in collaboration with the US non-profit organization CARB-X.

2022-04-17 - SNIPR BIOME commences dosing in Phase I CRISPR-based ...

Being developed in partnership with US-based non-profit organisation CARB-X, the investigational CRISPR therapy is intended to selectively...

2022-03-30 - CARB-X Awards Clarametyx Biosciences $3.89 Million in ...

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.1M35-36%N/A
#2
$4.1M35-15%N/A
#3
$7M356%$46M
#4
$3.7M35-46%$37.2M
#5
$3.9M35N/AN/A